Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,137 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PET Clear all
Completed Not applicable Interventional Results available

Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

NCT01222351
View directory record Official record
Conditions
Late Onset Alzheimer Disease
Interventions
BAY 94-9172 (Florbetaben)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
65 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 17, 2026, 5:22 AM EDT
Active, not recruiting No phase listed Observational

Using e-Nose Technology to Identify Early Lung Cancer

NCT04734145
View directory record Official record
Conditions
Lung; Node, Lung Cancer
Interventions
Breathprinting test
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Completed No phase listed Observational

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

NCT01410630
View directory record Official record
Conditions
Lymphoma, Lymphoma, Non-Hodgkin, Large B Cell Diffuse Lymphoma
Interventions
FLT-PET/CT, FDG-PET/CT, FLT
Diagnostic Test · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Omaha, Nebraska • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 17, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Neuroinflammation After Myocardial Infarction - Imaging Substudy

NCT03968445
View directory record Official record
Conditions
Myocardial Infarction
Interventions
[18F]DPA-714-PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Recruiting Phase 1 Interventional

Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)

NCT07027839
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Intravenous Ethanol, 18F-PF-06445974
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 17, 2026, 5:22 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Measuring Brain Inflammation in Autism

NCT03117530
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Minocycline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 17, 2026, 5:22 AM EDT
Recruiting Phase 4 Interventional

Staphylococcus Aureus Network Adaptive Platform Trial

NCT05137119
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Cefazolin, Penicillin, Clindamycin, Vancomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
Drug · Other · Radiation
Lead sponsor
University of Melbourne
Other
Eligibility
Not listed
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Recruiting Phase 1 Interventional

A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

NCT07688187
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide)
Drug
Lead sponsor
PeptiDream Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Recruiting No phase listed Observational

F 18 T807 Tau PET Imaging of Alzheimer's Disease

NCT02414347
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Withdrawn Not applicable Interventional

Intraoperative Imaging of a PET Positive Lymph Node(s) Using 18FDG and a Dual-Mode, Hand-Held Intraoperative Imager

NCT03561324
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Imaging Beta Probe (IBP)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 17, 2026, 5:22 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients

NCT03939780
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
[F18]RO-948, [F18]MK-6240, [F18]AV1451
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 17, 2026, 5:22 AM EDT
Completed No phase listed Observational

Biological Determinants of Peritoneal Dialysis

NCT02694068
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Peritoneal Equilibrium Test, 4 hour dwell of 2.5/4.25% dextrose solution
Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years and older
Enrollment
4,865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 17, 2026, 5:22 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

NCT04478318
View directory record Official record
Conditions
Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose, Positron-emission Tomography
Interventions
uEXPLORER/mCT, mCT/uEXPLORER
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Withdrawn Phase 1 Interventional

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT05950113
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Fludeoxyglucose F-18, Immunotherapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 17, 2026, 5:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

NCT03279523
View directory record Official record
Conditions
Alzheimer Disease, HIV
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 17, 2026, 5:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET

NCT01719497
View directory record Official record
Conditions
Obesity, Alcohol Dependence, High Stress
Interventions
[C-11]OMAR
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 17, 2026, 5:22 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

NCT06142396
View directory record Official record
Conditions
Multiple Myeloma, Renal Failure
Interventions
Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
Combination Product
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

NCT03678259
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
124I-p5+14 Injection
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 17, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 17, 2026, 5:22 AM EDT
Active, not recruiting Phase 1 Interventional

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

NCT05412290
View directory record Official record
Conditions
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
Interventions
Mosunetuzumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

NCT03675282
View directory record Official record
Conditions
Parkinson Disease, REM Sleep Behavior Disorder, Healthy
Interventions
(11C)PE2I, Ioflupane
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 100 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 17, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

NCT02609737
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 17, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

NCT01542879
View directory record Official record
Conditions
Cancer
Interventions
WB-DW-MR scan, 18-F-FDG PET scan, Ferumoxytol, 18-F-FDG PET/MR scan
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 40 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 5:22 AM EDT